Trial Profile

Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JS 203 (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions
Sponsors Shanghai Junshi Biosciences

Most Recent Events

19 Jun 2025 Planned End Date changed from 22 Feb 2025 to 30 Dec 2026.
19 Jun 2025 Planned primary completion date changed from 24 Dec 2024 to 30 Dec 2025.
30 Apr 2025 Results (n=48, data cut-off: 23 Dec 2024) assessing the safety profile and responses of JS203 Step-up Dosing administration, when pretreated with rituximab in patients with R/R B-NHL in the dose-escalation and dose-expansion phases, presented at the 116th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com